CN106822904A - 含akt抑制剂和ire1抑制剂的药物组合物及其应用 - Google Patents
含akt抑制剂和ire1抑制剂的药物组合物及其应用 Download PDFInfo
- Publication number
- CN106822904A CN106822904A CN201710135038.3A CN201710135038A CN106822904A CN 106822904 A CN106822904 A CN 106822904A CN 201710135038 A CN201710135038 A CN 201710135038A CN 106822904 A CN106822904 A CN 106822904A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- stf
- inhibitor
- cancer
- akt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 27
- 239000003112 inhibitor Substances 0.000 title claims abstract description 17
- 102100030013 Endoribonuclease Human genes 0.000 title claims abstract 6
- 101001010783 Homo sapiens Endoribonuclease Proteins 0.000 title claims abstract 6
- ULDXWLCXEDXJGE-UHFFFAOYSA-N MK-2206 Chemical group C=1C=C(C=2C(=CC=3C=4N(C(NN=4)=O)C=CC=3N=2)C=2C=CC=CC=2)C=CC=1C1(N)CCC1 ULDXWLCXEDXJGE-UHFFFAOYSA-N 0.000 claims abstract description 54
- 229940124640 MK-2206 Drugs 0.000 claims abstract description 54
- TVIVJHZHPKNDAQ-MHWRWJLKSA-N chembl3192687 Chemical group OC1=CC=C2C=CC=CC2=C1\C=N\S(=O)(=O)C1=CC=CS1 TVIVJHZHPKNDAQ-MHWRWJLKSA-N 0.000 claims abstract description 44
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 34
- 239000003814 drug Substances 0.000 claims abstract description 32
- 239000003197 protein kinase B inhibitor Substances 0.000 claims abstract description 14
- 229940126638 Akt inhibitor Drugs 0.000 claims abstract description 12
- GRZXWCHAXNAUHY-NSISKUIASA-N (2S)-2-(4-chlorophenyl)-1-[4-[(5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl]-1-piperazinyl]-3-(propan-2-ylamino)-1-propanone Chemical compound C1([C@H](C(=O)N2CCN(CC2)C=2C=3[C@H](C)C[C@@H](O)C=3N=CN=2)CNC(C)C)=CC=C(Cl)C=C1 GRZXWCHAXNAUHY-NSISKUIASA-N 0.000 claims abstract description 4
- WJNBSTLIALIIEW-UHFFFAOYSA-N 2-n-(3h-benzimidazol-5-yl)-4-n-(5-cyclopropyl-1h-pyrazol-3-yl)pyrimidine-2,4-diamine Chemical compound C1CC1C1=NNC(NC=2N=C(NC=3C=C4N=CNC4=CC=3)N=CC=2)=C1 WJNBSTLIALIIEW-UHFFFAOYSA-N 0.000 claims abstract description 4
- JDUBGYFRJFOXQC-KRWDZBQOSA-N 4-amino-n-[(1s)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide Chemical compound C1([C@H](CCO)NC(=O)C2(CCN(CC2)C=2C=3C=CNC=3N=CN=2)N)=CC=C(Cl)C=C1 JDUBGYFRJFOXQC-KRWDZBQOSA-N 0.000 claims abstract description 4
- SZFPYBIJACMNJV-UHFFFAOYSA-N perifosine Chemical compound CCCCCCCCCCCCCCCCCCOP([O-])(=O)OC1CC[N+](C)(C)CC1 SZFPYBIJACMNJV-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229950006331 ipatasertib Drugs 0.000 claims abstract 2
- 229950010632 perifosine Drugs 0.000 claims abstract 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 33
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 9
- 201000005202 lung cancer Diseases 0.000 claims description 9
- 208000020816 lung neoplasm Diseases 0.000 claims description 9
- 201000007270 liver cancer Diseases 0.000 claims description 8
- 208000014018 liver neoplasm Diseases 0.000 claims description 8
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 5
- 206010017758 gastric cancer Diseases 0.000 claims description 5
- 201000011549 stomach cancer Diseases 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 201000002313 intestinal cancer Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims description 2
- 208000017897 Carcinoma of esophagus Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 65
- 230000000694 effects Effects 0.000 abstract description 30
- 229940079593 drug Drugs 0.000 abstract description 29
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 abstract description 20
- 108091008611 Protein Kinase B Proteins 0.000 abstract description 18
- 210000004881 tumor cell Anatomy 0.000 abstract description 7
- 230000012010 growth Effects 0.000 abstract description 6
- 230000015572 biosynthetic process Effects 0.000 abstract description 4
- 239000002246 antineoplastic agent Substances 0.000 abstract description 3
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 2
- 239000000890 drug combination Substances 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 230000002079 cooperative effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 32
- 201000004101 esophageal cancer Diseases 0.000 description 32
- 230000002401 inhibitory effect Effects 0.000 description 15
- 201000011510 cancer Diseases 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 9
- 229960002949 fluorouracil Drugs 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 8
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 8
- 230000037361 pathway Effects 0.000 description 8
- 230000019491 signal transduction Effects 0.000 description 8
- 230000002195 synergetic effect Effects 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 7
- 230000006907 apoptotic process Effects 0.000 description 6
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 6
- 229960004316 cisplatin Drugs 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 108091006081 Inositol-requiring enzyme-1 Proteins 0.000 description 5
- 101150056418 XBP1 gene Proteins 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 102000038030 PI3Ks Human genes 0.000 description 4
- 108091007960 PI3Ks Proteins 0.000 description 4
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 230000004906 unfolded protein response Effects 0.000 description 4
- 101000779418 Homo sapiens RAC-alpha serine/threonine-protein kinase Proteins 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000005757 colony formation Effects 0.000 description 3
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000009521 phase II clinical trial Methods 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 210000003556 vascular endothelial cell Anatomy 0.000 description 3
- RTHHSXOVIJWFQP-UHFFFAOYSA-N 7-hydroxy-4-methyl-2-oxochromene-8-carbaldehyde Chemical compound O=CC1=C(O)C=CC2=C1OC(=O)C=C2C RTHHSXOVIJWFQP-UHFFFAOYSA-N 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000002301 combined effect Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000011242 molecular targeted therapy Methods 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000007730 Akt signaling Effects 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 229940123734 Endonuclease inhibitor Drugs 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- 101000669917 Homo sapiens Rho-associated protein kinase 1 Proteins 0.000 description 1
- 101000666295 Homo sapiens X-box-binding protein 1 Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 102000010995 Pleckstrin homology domains Human genes 0.000 description 1
- 108050001185 Pleckstrin homology domains Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102100039313 Rho-associated protein kinase 1 Human genes 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 102100038151 X-box-binding protein 1 Human genes 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000011226 adjuvant chemotherapy Methods 0.000 description 1
- 229940125516 allosteric modulator Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004791 biological behavior Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000005880 cancer cell killing Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- -1 heterocyclic alkyl phosphorylcholine Chemical compound 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 238000009522 phase III clinical trial Methods 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 229950004354 phosphorylcholine Drugs 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明涉及一种含AKT抑制剂和IRE1抑制剂的药物组合物及其在制备防治肿瘤药物中的应用，所述的AKT抑制剂选自MK‑2206、Perifosine、Ipatasertib或AZD5363，优选为MK‑2206；所述的IRE1抑制剂选自STF‑083010、APY29或4μ8C，优选为STF‑083010。所述的药物组合物以MK‑2206和STF‑083010联合用药，为肿瘤患者提供一种新的治疗方案，可有效抑制肿瘤细胞的生长和细胞克隆形成，效果显著优于单独用药，具有相加或协同效应，同时对正常细胞的毒副作用低，安全性高，可应用于制备抗肿瘤的药物领域。
Description
技术领域
本发明属于医药技术领域，具体涉及一种含AKT抑制剂和IRE1抑制剂的药物组合物及其应用。
背景技术
癌症是仅次于心血管疾病的高死亡率疾病，全球癌症患者和死亡病例都在不断地增加。新增癌症病例有近一半出现在亚洲，其中大部分在中国，中国新增癌症病例高居世界第一位。尤其是在肝癌、食管癌、胃癌和肺癌等4种恶性肿瘤中，中国新增病例和死亡人数均居世界首位。这些癌症的治疗虽然以手术为主，但由于早期患者一般无明显症状，在首次被确诊的癌症患者中，很多已为中晚期，失去了手术切除的机会，故非手术治疗在肿瘤的综合治疗中有着十分重要的地位。其中，化疗无论是术前化疗、术后辅助化疗还是姑息性化疗，在综合治疗中占据举足轻重的地位。目前常用的化疗药物多以长春瑞滨、紫杉醇、氟尿嘧啶、顺铂、5-氟尿嘧啶为主，其产生的化疗反应，如恶心呕吐较强烈以及对肝肾功能和骨髓损害等，一定程度上限制了其应用。
AKT信号传导通路是细胞内重要的信号传导通路之一，它参与调节肿瘤细胞的增殖、存活、迁移、黏附、肿瘤血管生成等过程，并在多种常见肿瘤(如乳腺癌、肺癌、胃癌、前列腺癌、宫颈癌和血液系统肿瘤)中均有高表达。因此，以AKT为靶点的分子靶向治疗也逐渐得到人们的重视。其中，MK-2206是一种高度选择性的AKT1/2/3抑制剂，其主要作用是抑制AKT磷酸化，对250种其他蛋白激酶没有抑制活性，目前已进入Ⅱ期临床试验研究。Perifosine(KRX-0401)是一种新型的AKT抑制剂，为一杂环的烷基磷酸胆碱，可靶向作用于Akt的pleckstrin同源结构域来抑制AKT的活性，表现出良好的抑制乳腺癌在内的多种实体瘤活性，目前已进入Ⅲ期临床试验研究。Ipatasertib(GDC-0068)是一种高选择性的广谱AKT抑制剂，靶向作用于AKT1/2/3，比作用于PKA选择性高620倍，目前已进入Ⅱ期临床试验研究。AZD5363作为AKT抑制剂，可有效抑制AKT(AKT1/2/3)的所有亚型，对P70S6K/PKA也具有相似的抑制效果，而对ROCK1/2抑制活性较低，目前已进入Ⅱ期临床试验研究。
肌醇需求激酶1(IRE1)是一种定位于内质网膜的跨膜蛋白，参于未折叠蛋白反应(UPR)信号通路中信息的传递。其中，IRE1α/Xbp1通路是UPR的重要传感通路，IRE1α通过感知内质网压力，使激酶区域自磷酸化进而激活核酸酶活性，在mRNA水平上剪切其下游转录因子Xbp1，激活一系列的UPR相关基因的转录，从而缓解内质网压力，还可通过非依赖Xbp1的途径，激活JNK，引发细胞的凋亡。STF-083010是一种特异性IRE1核酸内切酶抑制剂，具有剂量和时间依赖性的细胞抑制能力和细胞毒性，STF-083010可抑制XBP1剪接，抑制IRE1α的核酸内切酶活性，但不影响IRE1α的激酶活性。APY29是IRE1变构调节剂，能抑制IRE1R自磷酸化，并激活IRE1RNase活性。而4μ8C是高效的选择性IRE1抑制剂，它可阻断基底(RIDD)接近IRE1的活性部位，并选择性使Xbp1剪接作用和IRE1介导的mRNA降解失活。目前，关于IRE1α/Xbp1通路的研究多与脂肪代谢调控有关，很少涉及到肿瘤的防治。
随着肿瘤分子生物学的研究进展，肿瘤分子靶向治疗已成为肿瘤研究的热点，在多种肿瘤的治疗中发挥了重要的作用。然而，大部分肿瘤的生物学行为并非由单一信号传导通路所支配，而是多个信号传导通路共同起作用的，因此联合用药针对多靶点进行靶向治疗将不仅旨在减少或延缓耐药性的出现、降低毒性，而且通过多种药物对癌细胞杀伤的协同作用取得更好的疗效。目前，没有关于AKT抑制剂和IRE1抑制剂联合用药用于抗肿瘤的相关研究报道。
发明内容
为解决现有技术存在的问题，本发明的目的在于提供一种药物组合物及其在制备防治肿瘤的药物中的应用，具体涉及含有AKT抑制剂和IRE1抑制剂的药物组合物及其在制备治疗肺癌、肝癌、食管癌、肠癌、胃癌、脑瘤、胰腺癌、卵巢癌、乳腺癌或前列腺癌的药物中的应用。
本发明提供一种药物组合物，其包含有AKT抑制剂和IRE1抑制剂。
其中，所述的AKT抑制剂选自MK-2206、Perifosine(KRX-0401)、Ipatasertib(GDC-0068)或AZD5363。
所述的IRE1抑制剂选自STF-083010、APY29或4μ8C。
优选地，所述的AKT抑制剂为MK-2206。
优选地，所述的IRE1抑制剂为STF-083010。
优选地，所述的药物组合物包含有MK-2206和STF-083010。
进一步地，所述的药物组合物中MK-2206和STF-083010的摩尔浓度比为1～20:10～60。
优选地，所述的药物组合物中MK-2206和STF-083010的摩尔浓度比为5:40。
此外，本发明还请求保护上述的药物组合物在制备防治肿瘤药物中的应用，所述的肿瘤包括但不限于肺癌、肝癌、食管癌、肠癌、胃癌、脑瘤、胰腺癌、卵巢癌、乳腺癌或前列腺癌。
优选地，本发明请求保护上述的药物组合物在制备防治肺癌、肝癌、食管癌药物中的应用。
进一步地，所述的药物组合物可配以药学可接受的添加剂制成注射制剂或口服制剂，优选注射制剂，尤其是静脉注射制剂。
磷脂酰肌醇-3-激酶(PI3K)及蛋白激酶B(AKT)所组成的信号通路与肿瘤增殖、凋亡、转移、侵袭及血管生成密切相关。作为该通路的核心，异常活化的AKT通过磷酸化其下游分子(如mTOR)促进肿瘤恶性增殖及抵抗凋亡，并参与调节肿瘤对放化疗及靶向治疗的敏感性。特异性抑制AKT分子活化能有效阻断PI3K/AKT信号通路，抑制肿瘤增殖，促进凋亡。本发明人以MK-2206单独处理食管癌细胞株Kyse450、Kyse510、TE-1、Eca-109、EC9706，发现MK-2206对食管癌细胞的生长具有一定的抑制作用，使癌症细胞数明显减少，并且发现MK-2206通过抑制AKT及mTOR的磷酸化，使p-AKT和p-mTOR的表达显著下调，从而有效阻断PI3K/AKT/mTOR信号通路，充分发挥抑制肿瘤增殖，促进凋亡效果。
一方面，本发明人以MK-2206和STF-083010联合用药，观察其对食管癌、肺癌、肝癌细胞和正常血管内皮细胞的影响，结果发现，MK-2206和STF-083010联合用药，可显著抑制癌细胞的存活，减少癌细胞的数量，效果显著优于单独使用MK-2206或STF-083010，对食管癌、肺癌、肝癌细胞的抑制效果均显示出较佳的协同作用，同时，联合用药对正常血管内皮细胞的毒性较小。
另一方面，本发明人还考察了MK-2206和STF-083010联合用药对食管癌细胞克隆形成的影响，结果显示，与对照组以及单药组相比，联合用药对细胞克隆形成具有明显的协同抑制作用，联合用药组细胞克隆数量最少，同时体积也最小，表明MK-2206和STF-083010联合用药联合用药对抑制食管癌细胞克隆具有较佳的协同作用。
与现有技术相比，本发明的优势在于：
本发明提供一种用于防治肿瘤的药物组合物，具体为将AKT抑制剂和IRE1抑制剂组合使用，更具体为以MK-2206和STF-083010联合用药，为肿瘤患者提供一种新的治疗方案，所述的MK-2206和STF-083010联合用药，可有效抑制肿瘤细胞的生长和细胞克隆形成，效果显著优于单独用药，具有相加或协同效应，同时对正常细胞的毒副作用低，安全性高，可应用于制备抗肿瘤的药物领域。
附图说明
图1MK-2206单独使用对食管癌细胞生长的影响。
图2MK-2206单独使用对食管癌细胞形态的影响。
图3MK-2206单独使用对食管癌细胞mTOR/AKT通路的影响。
图4MK-2206与STF-083010联合作用对食管癌细胞生长的影响。
图5MK-2206与STF-083010联合作用对食管癌细胞形态的影响。
图6MK-2206与STF-083010联合作用对食管癌细胞的联用效果分析。
图7MK-2206、顺铂、5-氟尿嘧啶与STF-083010联合作用对肿瘤细胞及正常细胞的影响。
图8MK-2206与STF-083010联合作用对食管癌细胞克隆形成的影响。
具体实施方式
以下通过具体实施方式进一步描述本发明，但本发明不仅仅限于以下实施例。
实施例1MK-2206单独处理后对食管癌细胞生长的影响
首先检测Kyse450、Kyse510、TE-1、Eca-109、EC9706食管癌细胞对MK-2206单独使用的药物敏感性。
1、实验方法
将肿瘤细胞以每孔4000-6000个细胞的数量接种到96孔板，待细胞贴壁(24h)后，将MK-2206药物稀释成一定的梯度浓度，每浓度设5复孔，分为实验组及调零组加药。48h后采用MTT法进行细胞活力检测，每孔加入10μl MTT溶液，继续培养4h，小心吸除孔内液体，避免接触孔内结晶物，每孔加入100μl的DMSO，于恒速摇床上避光摇晃。待结晶物充分溶解后，在酶标仪上读取OD值(波长570nm，参考波长630nm)，测得吸光度A值。
生长抑制率的计算公式为：生长抑制率(％)＝(1-OD实验组/OD对照组)×100％。根据各浓度的抑制率可作图得到剂量反应曲线，作图软件为Graphpad，采用Logit法精确计算药物的IC50(half maximal inhibitory concentration)值。具体结果见图1和图2。
从图1可以看出，MK-2206对食管癌细胞株Kyse450、Kyse510、TE-1、Eca-109、EC9706的IC50值分别为14.3、12.4、9.4、7.6和11.5，表明MK-2206对食管癌细胞的生长具有一定的抑制作用。从图2也可以看出，MK-2206单独作用于食管癌细胞株Kyse450、Kyse510后，细胞数明显减少。
实施例2MK-2206单独使用对食管癌细胞mTOR/AKT通路的影响
利用Western blot方法检测经MK-2206单独处理及联合处理后食管癌细胞Kyse450和Kyse510细胞内mTOR/AKT通路相关蛋白的表达情况。先将Kyse450和Kyse510细胞分别以每孔2×105个细胞的密度接种至6孔板。待细胞贴壁后，按实施例1给药。处理48h后，分别收取各组细胞全蛋白。先经SDS电泳后，将蛋白转移至PVDF膜上，5％脱脂奶粉室温封闭1h，孵育所需检测的蛋白相对应的一抗，4℃孵育过夜。24h回收一抗，用TBST清洗3次，每次5min，之后孵育二抗，室温孵育1h。后用TBST清洗3次，每次5min，之后ECL显影，结果见图3。
从图3可以看出，在Kyse450和Kyse510细胞中，当用MK-2206单独处理后，p-AKT和p-mTOR的表达显著下调，说明MK-2206能够抑制AKT及mTOR的磷酸化，使p-AKT和p-mTOR的表达显著下调，从而有效阻断PI3K/AKT/mTOR信号通路，充分发挥抑制肿瘤增殖，促进凋亡效果。
实施例3MK-2206与STF-083010联合作用对食管癌细胞生长的影响
将人食管癌细胞Kyse450和Kyse510细胞以每孔4000-6000个细胞的数量接种到96孔板，待细胞贴壁后，加入5μM浓度MK-2206和40μM浓度STF-083010，培养48h后，每孔加入10μl浓度为5mg/ml的MTT溶液，继续培养4h，然后弃去培养液每孔加入100μl的DMSO，于恒速摇床上避光摇晃。待结晶物充分溶解后，在酶标仪上读取OD值(波长570nm，参考波长630nm)，读取每孔的吸光值，计算两药合用后细胞存活率。用CompuSyn软件进行协同作用综合因子(Combination Index,CI)分析，结果见图4。并通过显微镜观察5μM浓度MK-2206和40μM浓度STF-083010联合作用于食管癌细胞细胞形态变化，结果如图5。
如图4所示，5μM浓度MK-2206和40μM浓度STF-083010联合使用具有很好的联用效果。从图5可知，MK-2206与STF-083010两药联用后癌细胞数明显减少，细胞形态较正常组及单独用药组相比无明显变化。
CI值表示药物联合作用时的一个复合指数，CI值小于1、等于和大于1分别表示药物协同作用、增效作用和拮抗作用。从图6可以看出，MK-2206和STF-083010对食管癌细胞联合使用时，其CI值基本都在小于1的范围内，特别是Kyse450，表明MK-2206和STF-083010在本发明的用量范围内联合使用具有很好的协同作用。
实施例4MK-2206、顺铂、5-氟尿嘧啶和STF-083010联合作用对肿瘤细胞及正常细胞的影响
将Kyse450食管癌、Kyse510食管癌、A549肺癌、HepG2肝癌细胞和HUVEC正常血管内皮细胞以每孔3000-6000个细胞的数量接种到96孔板，待细胞贴壁后，加入对照组、5μM的MK-2206和40μM的STF-083010及联合用药组药物；另铺细胞Kyse450，按照如下方式进行加药：对照组、5μM MK-2206、40μM STF-083010、MK-2206+STF-083010、1μg/ml顺铂(CDDP)、顺铂(CDDP)+STF-083010、4μg/ml 5-氟尿嘧啶(5-FU)、5-氟尿嘧啶(5-FU)+STF-083010，培养48h后，每孔加入10μl浓度为5mg/ml的MTT溶液，继续培养4h，然后弃去培养液每孔加入100μl的DMSO，于恒速摇床上避光摇晃。待结晶物充分溶解后，在酶标仪上读取OD值(波长570nm，参考波长630nm)，读取每孔的吸光值，计算两药合用后的细胞存活及抑制率，结果见图7。
如图7所示，YM155和STF-083010在肿瘤细胞中组合使用具有很好的联合效果，且优于顺铂、5-氟尿嘧啶与STF-083010组合，而对正常HUVEC细胞的毒性较小。
实施例5MK-2206和STF-083010联合用药对食管癌细胞克隆形成的影响
将人食管癌细胞Kyse450和Kyse510细胞接种到6孔板，待细胞贴壁过夜后，将细胞分为对照组、MK-2206单药组、STF-083010单药组及MK-2206和STF-083010药物联合用药组，分别加入对应的培养基或者药物溶液，孵育7天，检测细胞平板克隆形成情况。结果如图8所示，与对照组以及单药组相比，联合用药对细胞克隆形成具有明显的协同抑制作用，联合用药组细胞克隆数量最少，同时体积也最小。
以上仅是本发明的优选实施方式，应当指出的是，上述优选实施方式不应视为对本发明的限制，本发明的保护范围应当以权利要求所限定的范围为准。对于本技术领域的普通技术人员来说，在不脱离本发明的精神和范围内，还可以做出若干改进和润饰，这些改进和润饰也应视为本发明的保护范围。
Claims (10)
1.一种药物组合物，其特征在于，所述的药物组合物包含有AKT抑制剂和IRE1抑制剂。
2.根据权利要求1所述的药物组合物，其特征在于，所述的AKT抑制剂选自MK-2206、Perifosine、Ipatasertib或AZD5363。
3.根据权利要求1所述的药物组合物，其特征在于，所述的IRE1抑制剂选自STF-083010、APY29或4μ8C。
4.根据权利要求2所述的药物组合物，其特征在于，所述的AKT抑制剂为MK-2206。
5.根据权利要求3所述的药物组合物，其特征在于，所述的IRE1抑制剂为STF-083010。
6.根据权利要求1所述的药物组合物，其特征在于，所述的药物组合物包含有MK-2206和STF-083010。
7.根据权利要求6所述的药物组合物，其特征在于，所述的药物组合物中MK-2206和STF-083010的摩尔浓度比为1～20:10～60。
8.根据权利要求7所述的药物组合物，其特征在于，所述的药物组合物中MK-2206和STF-083010的摩尔浓度比为5:40。
9.根据权利要求1-8任一所述的药物组合物在制备防治肿瘤药物中的应用。
10.根据权利要求9所述的应用，其特征在于，所述的肿瘤为肺癌、肝癌、食管癌、肠癌、胃癌、脑瘤、胰腺癌、卵巢癌、乳腺癌或前列腺癌。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710135038.3A CN106822904B (zh) | 2017-03-08 | 2017-03-08 | 含akt抑制剂和ire1抑制剂的药物组合物及其应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710135038.3A CN106822904B (zh) | 2017-03-08 | 2017-03-08 | 含akt抑制剂和ire1抑制剂的药物组合物及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106822904A true CN106822904A (zh) | 2017-06-13 |
| CN106822904B CN106822904B (zh) | 2019-10-25 |
Family
ID=59143336
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710135038.3A Active CN106822904B (zh) | 2017-03-08 | 2017-03-08 | 含akt抑制剂和ire1抑制剂的药物组合物及其应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106822904B (zh) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020019107A1 (en) * | 2018-07-23 | 2020-01-30 | Fosun Orinove Pharmatech, Inc. | IRE1α INHIBITOR IN COMBINATION WITH CANCER THERAPEUTIC AGENT FOR CANCER TREATMENT |
| WO2020020155A1 (en) * | 2018-07-23 | 2020-01-30 | Fosun Orinove Pharmatech, Inc. | IRE1α INHIBITOR IN COMBINATION WITH CANCER THERAPEUTIC AGENT FOR CANCER TREATMENT |
| WO2020087522A1 (en) * | 2018-11-02 | 2020-05-07 | Fosun Orinove Pharmatech, Inc. | IRE1α inhibitor in combination with cancer therapeutic agent for cancer treatment |
| CN116549442A (zh) * | 2023-06-08 | 2023-08-08 | 复旦大学 | Stf-083010在制备防治主动脉夹层药物中的应用 |
| CN119656157A (zh) * | 2025-01-13 | 2025-03-21 | 安徽农业大学 | 4μ8C在制备防治家蚕核型多角体病毒制剂中的应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1934072A (zh) * | 2004-01-30 | 2007-03-21 | 派普林生物脂股份有限公司 | 治疗和载体分子 |
| CN102015606A (zh) * | 2007-06-08 | 2011-04-13 | 满康德股份有限公司 | IRE-1α抑制剂 |
| WO2014176348A1 (en) * | 2013-04-23 | 2014-10-30 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Inhibitors of the ire-1/xbp-1 pathway and methods of using thereof |
-
2017
- 2017-03-08 CN CN201710135038.3A patent/CN106822904B/zh active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1934072A (zh) * | 2004-01-30 | 2007-03-21 | 派普林生物脂股份有限公司 | 治疗和载体分子 |
| CN102015606A (zh) * | 2007-06-08 | 2011-04-13 | 满康德股份有限公司 | IRE-1α抑制剂 |
| WO2014176348A1 (en) * | 2013-04-23 | 2014-10-30 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Inhibitors of the ire-1/xbp-1 pathway and methods of using thereof |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020019107A1 (en) * | 2018-07-23 | 2020-01-30 | Fosun Orinove Pharmatech, Inc. | IRE1α INHIBITOR IN COMBINATION WITH CANCER THERAPEUTIC AGENT FOR CANCER TREATMENT |
| WO2020020155A1 (en) * | 2018-07-23 | 2020-01-30 | Fosun Orinove Pharmatech, Inc. | IRE1α INHIBITOR IN COMBINATION WITH CANCER THERAPEUTIC AGENT FOR CANCER TREATMENT |
| WO2020087522A1 (en) * | 2018-11-02 | 2020-05-07 | Fosun Orinove Pharmatech, Inc. | IRE1α inhibitor in combination with cancer therapeutic agent for cancer treatment |
| CN116549442A (zh) * | 2023-06-08 | 2023-08-08 | 复旦大学 | Stf-083010在制备防治主动脉夹层药物中的应用 |
| CN119656157A (zh) * | 2025-01-13 | 2025-03-21 | 安徽农业大学 | 4μ8C在制备防治家蚕核型多角体病毒制剂中的应用 |
| CN119656157B (zh) * | 2025-01-13 | 2025-06-10 | 安徽农业大学 | 4μ8C在制备防治家蚕核型多角体病毒制剂中的应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106822904B (zh) | 2019-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106822904B (zh) | 含akt抑制剂和ire1抑制剂的药物组合物及其应用 | |
| Riahi-Chebbi et al. | The Phenolic compound Kaempferol overcomes 5-fluorouracil resistance in human resistant LS174 colon cancer cells | |
| Hu et al. | Lanatoside C inhibits cell proliferation and induces apoptosis through attenuating Wnt/β-catenin/c-Myc signaling pathway in human gastric cancer cell | |
| Philipp et al. | Cancer and necroptosis: friend or foe? | |
| Mohassab et al. | STAT3 transcription factor as target for anti-cancer therapy | |
| Lu et al. | Luteolin induces apoptosis in vitro through suppressing the MAPK and PI3K signaling pathways in gastric cancer | |
| CN101842095B (zh) | 肿瘤治疗的配方,方法和靶目标 | |
| CN106963769A (zh) | 含pi3k抑制剂和perk抑制剂的药物组合物及其应用 | |
| CN106822905A (zh) | 含Survivin抑制剂和IRE1抑制剂的药物及用途 | |
| KR20170084034A (ko) | 암 치료용 의약 조성물 제조에서의 아젤니디핀의 용도 | |
| Ma et al. | Acteoside as a potential therapeutic option for primary hepatocellular carcinoma: a preclinical study | |
| Feng et al. | Luteolin, an aryl hydrocarbon receptor ligand, suppresses tumor metastasis in vitro and in vivo | |
| CN102526022A (zh) | 表没食子儿茶素没食子酸酯在制备抗肿瘤药物中的应用 | |
| Wang et al. | Identification of WT1 as determinant of heptatocellular carcinoma and its inhibition by Chinese herbal medicine Salvia chinensis Benth and its active ingredient protocatechualdehyde | |
| Guo et al. | (-)-β-hydrastine suppresses the proliferation and invasion of human lung adenocarcinoma cells by inhibiting PAK4 kinase activity | |
| Ramchandani et al. | The multifaceted antineoplastic role of pyrimethamine against human malignancies | |
| Li et al. | Proapoptotic and Growth-inhibitory Effects of Plumbagin on Human Gastric Cancer Cells Via Suppression of Signal Transducer and Activator of Transcription 3 and Protein Kinase B. | |
| Lu et al. | Anticancer effect of resibufogenin on gastric carcinoma cells through the phosphoinositide 3‑kinase/protein kinase B/glycogen synthase kinase 3β signaling pathway | |
| Xu et al. | Cucurbitacin C suppresses the progression of pancreatic ductal adenocarcinoma via inhibition of the cGMP-PKG-VASP axis | |
| CN105476996B (zh) | 姜黄素与阿法替尼联合治疗非小细胞肺癌的用途 | |
| CN106974908B (zh) | 含有hdac抑制剂和ire1抑制剂的药物组合物及用途 | |
| TWI797426B (zh) | 西奧羅尼用於小細胞肺癌的治療 | |
| CN112263578B (zh) | Tipranavir在制备杀伤肿瘤干细胞和肿瘤细胞的癌症治疗药物中的用途 | |
| CN113786491B (zh) | 一种含汉防己甲素、二氢槲皮素或槲皮素的抗肿瘤联用制剂 | |
| CN103417533A (zh) | Tpca-1作为stat3信号抑制剂在制备抗肿瘤药物中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |